Pharma Industry News -
Home » Posts tagged with » Pharma Industry News

US FDA concerned about quality of medicines sold in India

US FDA concerned about quality of medicines sold in India

The US Food and Drug Administration (UFDA), on Friday said it was concerned about the quality and efficacy of medicines sold in India. As per the ETHealthworld.com, this could be the first time that a foreign regulator of drugs has commented about the medicine quality in India. The last two years have seen Indian pharma […]

Clinical research provider Chiltern opens process and technology center in Bangalore

Clinical research provider Chiltern opens process and technology center in Bangalore

Global contract research organization Chiltern has opened a new process and technology center in India at Bangalore to improve its global data capabilities. The new process and technology office at Bangalore, Karnataka is a direct result of its continued success, stated Chiltern which had opened its first office in India with just five programmers, more […]

Genprex lung cancer drug Oncoprex phase 2 trial returns positive interim results

Genprex lung cancer drug Oncoprex phase 2 trial returns positive interim results

Lung cancer drug candidate Oncoprex developed by US based Genprex has demonstrated positive interim data in its ongoing phase 2 clinical trial. Dubbed NCT01455389, the phase 2 trial of Genprex’s drug intended to treat non-small cell lung cancer (NSCLC) is being evaluated in combination with the tyrosine kinase inhibitor (TKI) – erlotinib (Tarceva). Held at […]

Strongbridge buys US rights of Taro’s periodic paralysis drug Keveyis

Strongbridge buys US rights of Taro’s periodic paralysis drug Keveyis

Pennsylvania based Strongbridge Biopharma has bought the US rights of Taro Pharmaceutical’s periodic paralysis drug Keveyis (dichlorphenamide) for $8.5 million. Keveyis was approved by the U.S. Food and Drug Administration (FDA) last year to treat primary hyperkalemic and hypokalemic periodic paralysis. It was granted orphan designation status up to August 2022. Hyperkalemic and hypokalemic periodic […]